Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Antibiotic Prophylaxis; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Rheumatoid Arthritis
Interventions: Lovastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Depression, Bipolar
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 33 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Oregon Research Institute; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Health Adult Subjects
Interventions: Omaveloxolone, Moxifloxacin; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T, Placebo; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Norwalk, California • Orange, California • Santa Ana, California + 10 more

Conditions: Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions: Visual Performance tests, Brain-computer interface; Diagnostic Test · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Healthy Liver/Hígado Sano program, Usual standard of care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Human Papillomavirus
Interventions: txt2protect, Sexual Health Control; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Birmingham, Alabama • Escondido, California • Fresno, California + 54 more

Conditions: Social Anxiety Disorder
Interventions: MDMA, Psychotherapy; Drug · Behavioral
Lead sponsor: Jason B Luoma; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Plaque Psoriasis
Interventions: calcitriol ointment, placebo comparator; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more

Conditions: Demodex Blepharitis
Interventions: GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, GLK-321 high dose QD, Placebo BID; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: Delirium, Postoperative Cognitive Dysfunction
Interventions: Lumosity; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 60 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease
Interventions: Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 41
States / cities: Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more

Conditions: Helicobacter Pylori Infection
Interventions: Amoxicillin, Omeprazole, Clarithromycin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Artery Hypertension
Interventions: GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions: JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Glimepiride, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more

Conditions: Nasal Polyps
Interventions: Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more

Conditions: Degenerative Disc Disease
Interventions: Intradiscal rhGDF-5, Water for injection; Drug · Other
Lead sponsor: DePuy Spine; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more

Conditions: Cerebral Edema, Saline Solution, Hypertonic
Interventions: 3% Sodium Chloride, 23.4% Sodium Chloride, 8.4% Sodium Bicarbonate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Enhancing Support for Women With Type 2 Diabetes: Follow-Up

A TQTc Study for Omaveloxolone

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver Disease

txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Social Anxiety MDMA-Assisted Therapy Investigation

Plaque Psoriasis Study in Pediatric Subjects

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Prevention of Early Postoperative Decline

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation